-quality large-scale, multicenter
randomized clinical
trials (RCTs) are designed and implemented to promote
Deal, C,
Steelman, J,
Vlachopapadopoulou, E,
Stawerska, R,
Silverman, LA;,
Phillip, M,
Kim, HS,
Ko, CW,
Malievskiy, O,
Cara, JF,
Roland, CL,
Taylor, CT,
Valluri, SR,
Wajnrajch, MP,
Pastrak, A,
Miller, BS (2022) .
Methods: In this 12-month, open-label,
randomized, active-
controlled, parallel-group, phase 3 study
Wu, JN,
Al-Zahrani, A,
Beylerli, O,
Sufianov, R,
Talybov, R,
Meshcheryakova, S,
Sufianova, G,
Gareev, I,
Sufianov, A (2022) Central Register of
Controlled Trials, and Web of Science database and obtained different sets of data
Zhao, S.,
Sufianova, G.,
Shapkin, A.,
Mashkin, A.,
Meshcheryakova, S.,
Han, DY (2022) at the cervical (C3-C5) and lower thoracic (Th9-Th10) levels.
Results: In all patients, on the 5th day of
trialHan, Dayong,
Teng, Lei,
Wang, Xiaoxiong,
Zhen, Yunbo,
Chen, Xiaofeng,
Yang, Mingchun,
Gao, Ming,
Yang, Guang,
Han, Mingyang,
Wang, Ligang,
Xu, Jiajun,
Li, Yue,
Shumadalova, Alina,
Zhao, Shiguang (2022) , and the dose recommended for a phase II
trial is 1.5 mg. Copyright © 2022 Han, Teng, Wang, Zhen, Chen, Yang
Shnayder, N.A.,
Novitsky, M.A.,
Neznanov, N.G.,
Limankin, O.V.,
Asadullin, A.R.,
Petrov, A.V.,
Dmitrenko, D.V.,
Narodova, E.A.,
Popenko, N.V.,
Nasyrova, R.F. (2022) corresponding to the purpose of this study were analyzed in this
topic review. Results: Overlap in the symptoms
Timasheva, Y,
Nasibullin, TR,
Tuktarova, IA,
Erdman, VV,
Galiullin, TR,
Zaplakhova, OV,
Bakhtiiarova, KZ (2022) -analysis of the study results in three populations was performed under fixed effects and
random effects models.
Results
Balkhiyarova, Z.,
Luciano, R.,
Kaakinen, M.,
Ulrich, A.,
Shmeliov, A.,
Bianchi, M.,
Chioma, L.,
Dallapiccola, B.,
Prokopenko, I.,
Manco, M. (2022) causal relationships between obesity and FG/FI using one-sample Mendelian
randomization analyses in both
in epithelial and endothelial cell sheets and
controlling paracellular permeability. In the last two decades